Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001562762-23-000117
Filing Date
2023-03-16
Accepted
2023-03-16 17:10:28
Documents
18

Document Format Files

Seq Description Document Type Size
1 PRE 14A sava-20221231xdef14a.htm   iXBRL PRE 14A 1857440
6 GRAPHIC sava-20221231xdef14ag001.jpg GRAPHIC 3888
7 GRAPHIC sava-20221231xdef14ag002.jpg GRAPHIC 22987
8 GRAPHIC sava-20221231xdef14ag003.jpg GRAPHIC 373243
9 GRAPHIC sava-20221231xdef14ag004.jpg GRAPHIC 464405
  Complete submission text file 0001562762-23-000117.txt   5000089

Data Files

Seq Description Document Type Size
2 EX-101.SCH sava-20221231.xsd EX-101.SCH 8649
3 EX-101.DEF sava-20221231_def.xml EX-101.DEF 19179
4 EX-101.LAB sava-20221231_lab.xml EX-101.LAB 31053
5 EX-101.PRE sava-20221231_pre.xml EX-101.PRE 25839
12 EXTRACTED XBRL INSTANCE DOCUMENT sava-20221231xdef14a_htm.xml XML 277457
Mailing Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731
Business Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731 512-501-2444
CASSAVA SCIENCES INC (Filer) CIK: 0001069530 (see all company filings)

EIN.: 911911336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 000-29959 | Film No.: 23739725
SIC: 2834 Pharmaceutical Preparations